Showing 97 to 108 of 151 results
Eli Lilly Exceeds Profit Forecasts Despite Sales Disappointments
Eli Lilly, exceeding analysts' expectations, forecasts higher-than-expected annual profit despite recent sales misses for its Mounjaro and Zepbound drugs; the company's stock rose 1 percent in premarket trading.
Eli Lilly Exceeds Profit Forecasts Despite Sales Disappointments
Eli Lilly, exceeding analysts' expectations, forecasts higher-than-expected annual profit despite recent sales misses for its Mounjaro and Zepbound drugs; the company's stock rose 1 percent in premarket trading.
Progress
36% Bias Score
Merck Stock Plunges 10% on Lower Sales Forecast Amidst China Gardasil Shipment Pause
Merck's stock fell 10% following a lower-than-expected 2025 sales forecast primarily due to a temporary Gardasil vaccine shipment pause to China to address excess inventory and support its Chinese partner amidst slumping sales and a weakening Chinese economy.
Merck Stock Plunges 10% on Lower Sales Forecast Amidst China Gardasil Shipment Pause
Merck's stock fell 10% following a lower-than-expected 2025 sales forecast primarily due to a temporary Gardasil vaccine shipment pause to China to address excess inventory and support its Chinese partner amidst slumping sales and a weakening Chinese economy.
Progress
44% Bias Score
Novartis Q4 Sales Beat Expectations Despite Full-Year Miss
Novartis reported better-than-expected Q4 2024 net sales of \$13.2 billion (16% increase), driven by Entresto and Cosentyx, exceeding analyst estimates but slightly missing its full-year sales forecast of \$50.47 billion; the company projects continued, albeit moderated, growth in 2025.
Novartis Q4 Sales Beat Expectations Despite Full-Year Miss
Novartis reported better-than-expected Q4 2024 net sales of \$13.2 billion (16% increase), driven by Entresto and Cosentyx, exceeding analyst estimates but slightly missing its full-year sales forecast of \$50.47 billion; the company projects continued, albeit moderated, growth in 2025.
Progress
24% Bias Score
Long Waits at Athens EOPYY Pharmacies Expose Healthcare System Strain
Long queues at Athens' EOPYY pharmacies cause significant delays for patients needing high-cost medications, highlighting understaffing and insufficient geographical distribution of these facilities, impacting patients' health and well-being.
Long Waits at Athens EOPYY Pharmacies Expose Healthcare System Strain
Long queues at Athens' EOPYY pharmacies cause significant delays for patients needing high-cost medications, highlighting understaffing and insufficient geographical distribution of these facilities, impacting patients' health and well-being.
Progress
56% Bias Score
Medicare Price Negotiations Expand to 15 Drugs, Including Ozempic and Wegovy
The Biden administration announced 15 drugs, including Ozempic and Wegovy, for Medicare price negotiations under the Inflation Reduction Act, aiming to lower drug costs for 50 million beneficiaries; the new prices are expected to take effect in January 2027, although the incoming Trump administratio...
Medicare Price Negotiations Expand to 15 Drugs, Including Ozempic and Wegovy
The Biden administration announced 15 drugs, including Ozempic and Wegovy, for Medicare price negotiations under the Inflation Reduction Act, aiming to lower drug costs for 50 million beneficiaries; the new prices are expected to take effect in January 2027, although the incoming Trump administratio...
Progress
36% Bias Score
575 Brand-Name Drug Prices Increase in Early 2025
On January 1st and 2nd, 2025, 575 brand-name drugs increased in price, including Ozempic and Paxlovid; the median increase was 4%, exceeding inflation and potentially impacting consumer costs depending on insurance coverage and formulary placement.
575 Brand-Name Drug Prices Increase in Early 2025
On January 1st and 2nd, 2025, 575 brand-name drugs increased in price, including Ozempic and Paxlovid; the median increase was 4%, exceeding inflation and potentially impacting consumer costs depending on insurance coverage and formulary placement.
Progress
36% Bias Score
Eleven Blockbuster Drugs to Transform Medicine by 2030
Clarivate's 2025 Drugs to Watch report identifies eleven innovative medicines projected to become blockbusters by 2030, significantly impacting various therapeutic areas, with diabetes/obesity and atopic dermatitis treatments anticipated to lead in revenue generation.
Eleven Blockbuster Drugs to Transform Medicine by 2030
Clarivate's 2025 Drugs to Watch report identifies eleven innovative medicines projected to become blockbusters by 2030, significantly impacting various therapeutic areas, with diabetes/obesity and atopic dermatitis treatments anticipated to lead in revenue generation.
Progress
36% Bias Score
Novartis Reports Record 2024 Sales Despite Morphosys Write-Down
Novartis announced record 2024 financial results: \$50.3 billion in sales (up 11%), \$19.5 billion in operating core earnings (up 19%), and \$11.9 billion in net income (up 39%), driven by innovative medicines; however, a \$900 million write-down from the Morphosys acquisition impacted the results.
Novartis Reports Record 2024 Sales Despite Morphosys Write-Down
Novartis announced record 2024 financial results: \$50.3 billion in sales (up 11%), \$19.5 billion in operating core earnings (up 19%), and \$11.9 billion in net income (up 39%), driven by innovative medicines; however, a \$900 million write-down from the Morphosys acquisition impacted the results.
Progress
44% Bias Score
Mixed Results Shake Up Midday Trading
Midday trading saw significant stock fluctuations: Colgate-Palmolive fell 4% due to missed revenue expectations and a weak sales forecast, while KLA Corporation climbed 2% after exceeding fiscal second-quarter expectations. Other notable changes include Vertex Pharmaceuticals (up 7%), Deckers Outdoo...
Mixed Results Shake Up Midday Trading
Midday trading saw significant stock fluctuations: Colgate-Palmolive fell 4% due to missed revenue expectations and a weak sales forecast, while KLA Corporation climbed 2% after exceeding fiscal second-quarter expectations. Other notable changes include Vertex Pharmaceuticals (up 7%), Deckers Outdoo...
Progress
40% Bias Score
LVMH Overtakes Novo Nordisk as Europe's Most Valuable Company
LVMH has overtaken Novo Nordisk as Europe's most valuable company, with a market cap of €341 billion versus Novo Nordisk's €261 billion, due to strong performance in the luxury sector and concerns about Novo Nordisk's pricing in the US.
LVMH Overtakes Novo Nordisk as Europe's Most Valuable Company
LVMH has overtaken Novo Nordisk as Europe's most valuable company, with a market cap of €341 billion versus Novo Nordisk's €261 billion, due to strong performance in the luxury sector and concerns about Novo Nordisk's pricing in the US.
Progress
36% Bias Score
Medicare Selects 15 More Drugs for Price Negotiation
Medicare selected 15 more top-selling prescription drugs for price negotiations under the Inflation Reduction Act, impacting 5.3 million beneficiaries and $41 billion in spending, with expected savings of $1.5 billion in 2027, but the incoming Trump administration may alter the program.
Medicare Selects 15 More Drugs for Price Negotiation
Medicare selected 15 more top-selling prescription drugs for price negotiations under the Inflation Reduction Act, impacting 5.3 million beneficiaries and $41 billion in spending, with expected savings of $1.5 billion in 2027, but the incoming Trump administration may alter the program.
Progress
48% Bias Score
J&J's Lung Cancer Drug Extends Life by at Least a Year
Johnson & Johnson announced Tuesday that its two-drug lung cancer regimen, Rybrevant and Lazcluze, extends life expectancy by at least a year compared to AstraZeneca's Tagrisso, based on a pivotal trial, though the regimen has more side effects.
J&J's Lung Cancer Drug Extends Life by at Least a Year
Johnson & Johnson announced Tuesday that its two-drug lung cancer regimen, Rybrevant and Lazcluze, extends life expectancy by at least a year compared to AstraZeneca's Tagrisso, based on a pivotal trial, though the regimen has more side effects.
Progress
60% Bias Score
Showing 97 to 108 of 151 results